J2KBIO Co., Ltd.

As of June 30, 2026, J2KBIO Co., Ltd. carries a market capitalization of 43.80B, placing it among publicly traded companies globally. Its enterprise value stands at 34.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, J2KBIO Co., Ltd. has 5.85M shares outstanding.

As of June 30, 2026, J2KBIO Co., Ltd. trades at a trailing price-to-earnings ratio of 7.53. The price-to-sales ratio is 1.00, and the price-to-book ratio stands at 1.20.

As of June 30, 2026, J2KBIO Co., Ltd. trades at an EV/EBITDA multiple of 4.71 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.80 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.38 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. J2KBIO Co., Ltd. trades at an EV/FCF ratio of 9.76, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 34.93B versus a market cap of 43.80B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, J2KBIO Co., Ltd. maintains a current ratio of 4.11, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.71, indicating elevated leverage, while an interest coverage ratio of 172.96 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, J2KBIO Co., Ltd. posted a return on equity (ROE) of 16.91, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.17 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.66, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.50, useful for judging operating efficiency across full business cycles. The company generates approximately 753.64M in revenue per employee across its workforce of 58.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.97 indicates how many times J2KBIO Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, J2KBIO Co., Ltd. recorded 1.19B in income tax expense. That works out to an effective tax rate of 16.96, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 7.00B, leaving 5.81B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, J2KBIO Co., Ltd.'s stock has declined approximately 3.72% over the past 52 weeks. The 50-day moving average sits at 9,342.60, while the 200-day moving average is 8,526.65.

Over the twelve months ended June 30, 2026, J2KBIO Co., Ltd. generated 43.90B in revenue and converted that into 5.81B in net income, yielding earnings per share of 994.28. EBITDA reached 7.42B, while operating income came in at 6.50B.

As of June 30, 2026, J2KBIO Co., Ltd. holds 9.85B in cash and equivalents against 989.70M in total debt, resulting in a net debt position of -8.81B. Total book value stands at 36.57B, with working capital of 17.97B providing operational flexibility.

J2KBIO Co., Ltd. produced 5.15B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.61B in capital expenditures, free cash flow totaled 3.54B - equivalent to 606.20 per share.

Over the twelve months ended June 30, 2026, J2KBIO Co., Ltd. posted a gross margin of 39.64, reflecting its pricing power and cost economics. The operating margin of 14.80 and net profit margin of 13.24 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, J2KBIO Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.09, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.98, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to J2KBIO Co., Ltd. shareholders.

As of June 30, 2026, J2KBIO Co., Ltd. has an Altman Z-Score of 6.44, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.